DUBLIN--(BUSINESS WIRE)--The "Bulk Paclitaxel - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
Bulk Paclitaxel market worldwide is projected to grow by US$106.2 Million, driven by a compounded growth of 12.1%. Natural Paclitaxel API, one of the segments analyzed and sized in this study, displays the potential to grow at over 11.5%.
The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$65.9 Million by the year 2025, Natural Paclitaxel API will bring in healthy gains adding significant momentum to global growth.
Representing the developed world, the United States will maintain a 10.7% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$4.2 Million to the region's size and clout in the next 5 to 6 years. Over US$3.5 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Natural Paclitaxel API will reach a market size of US$2.9 Million by the close of the analysis period.
As the world's second largest economy and the new game changer in global markets, China exhibits the potential to grow at 15.4% over the next couple of years and add approximately US$25.2 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders.
Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio.
Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.
Competitors identified in this market include:
- Fresenius Kabi AG
- Guilin Huiang Biochemistry Pharmaceutical Co., Ltd.
- Hainan Yeshanyuan Pharmaceutical Co., Ltd.
- Novasep Holding SAS
- Phyton Biotech
- Poly Medicure Ltd.
- Samyang Biopharmaceuticals Corporation
- ScinoPharm Taiwan Ltd.
- Teva API, Inc.
Yunnan Hande Bio-tech Co., Ltd./Hande Bio-Source, Inc. (HBS)
For more information about this report visit https://www.researchandmarkets.com/r/tlzd38